Almirall SA - Company Profile

Powered by

All the data and insights you need on Almirall SA in one report.

$395 $295
Buy Report View Sample
  • Save hours of research time and resources with
    our up-to-date Almirall SA Strategy Report

  • Understand Almirall SA position in the market,
    performance and strategic initiatives.

  • Gain competitive edge and increase your
    chances of success

Back to companies

Almirall SA: Overview

Select Item

Related keylists

Almirall SA (Almirall) is a specialty pharmaceutical company that researches, develops, manufactures, and commercializes proprietary medicines and licensed products. The company’s major area of focus is dermatology covering psoriasis, eczema, psoriasis, oncodermatology, onychomicosis, actinic keratosis, acne, and other skin infections. It also develops products for autoimmune diseases including rheumatoid arthritis and multiple sclerosis; and gastrointestinal diseases including irritable bowel syndrome with constipation. The company also works together with small and medium-sized companies and healthcare professionals to develop medical solutions and provide them to patients. It operates through affiliates in Europe and Central America and has R&D centers in Spain and Germany. Almirall is headquartered in Barcelona, Spain.

 Gain a 360-degree view of Almirall SA and make more informed decisions for your business Gain a 360-degree view of Almirall SA and make more informed decisions for your business Find out more
Headquarters Spain
Address Ronda General Mitre, 151, Barcelona, 08022
Website www.almirall.es
Telephone 34 932 913000
No of Employees 1,904
Industry Pharmaceuticals and Healthcare
Ticker Symbol & Exchange ALM (MCE)
Revenue (2022) $967.4M 3.6% (2022 vs 2021)
EPS XYZ
Net Income (2022) XYZ -998.7% (2022 vs 2021)
Market Cap* $1.8B
Net Profit Margin (2022) XYZ -960.0% (2022 vs 2021)
* As of and is in US$
View Almirall SA financials
Gain access to our premium signals and make informed decisions for your business Gain access to our premium signals and make informed decisions for your business Find out more

Almirall SA premium industry data and analytics

170+

Clinical Trials

Determine Almirall SA go-to-market proposition and gain insight into the company’s clinical operations, recruitment, and trial strategy.

130+

Marketed Drugs

Understand Almirall SA’s commercialized product portfolio to stay one step ahead of the market.

60+

Pipeline Drugs

Identify which of Almirall SA’s products will be commercialized, helping you to better contend with shifting product portfolios, and allowing you to stay one step ahead of the market.

30+

Catalyst Calendar

Proactively evaluate Almirall SA’s catalyst impacts to stay ahead of the competition & improve corporate planning. Bolster business development with timely opportunities.

30+

Sales & Consensus Forecasts

Understand the current and future drug revenue for Almirall SA and assess market opportunity for new entrants with patient population 8-year forecasts.

30+

Insights

Remove risk and uncertainty, gain a competitive edge and secure actionable leads with access to company-related investigative journalist content.

7

Regulatory Milestones

Track drug and patent expiries along with geographies impacted.

1

IT Services Contracts

Improve competitive bidding with insights into all publicly disclosed IT services contracts for Almirall SA (including IT outsourcing, business process outsourcing, systems integration & consulting and more).

1

ICT Spend & Tech Priorities

IT Client Prospector provides intelligence on Almirall SA’s likely spend across technology areas enabling you to understand the digital strategy.

Products and Services

Products Brands
Generic Medicines -
Dermatology Products Airtal
Over-the-Counter Products Almax
XYZ XYZ
XYZ XYZ
XYZ XYZ
Understand Almirall SA portfolio and identify potential areas for collaboration Understand Almirall SA portfolio and identify potential areas for collaboration Find out more

History

History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.

Year Event Description
2024 Contracts/Agreements In January, the company and Microsoft entered into a partnership to advance medical dermatology and foster the development of personalized drugs.
2023 Contracts/Agreements In December, the company entered into a partnership with etherna to introduce a new mRNA-based therapies for severe skin diseases.
2023 Contracts/Agreements In November, the company and Absci Corporation entered into a drug discovery partnership to develop and commercialize AI-designed therapeutics to fight chronic and debilitating dermatological diseases.
Dive into past operations, including product releases, deals, acquisitions & more Dive into past operations, including product releases, deals, acquisitions & more Find out more
Image for loader

Competitor Comparison

Key Parameters Almirall SA GSK plc Laboratorios Farmaceuticos Rovi SA ALK-Abello AS Esteve Pharmaceuticals SA
Headquarters Spain United Kingdom Spain Denmark Spain
City Barcelona Brentford Madrid Hoersholm Barcelona
State/Province - England Madrid - Barcelona
No. of Employees 1,904 70,212 2,111 2,824 1,824
Entity Type Public Public Public Public Private
Benchmark the company against the market with exclusive information on key competitors Benchmark the company against the market with exclusive information on key competitors Find out more
Chart Financial activity with access to more key stats Chart Financial activity with access to more key stats Find out more
Executives
Name Position Board Since Age
Carlos Gallardo Pique Chairman; Director - Proprietary; Chief Executive Officer Executive Board 2023 -
Mike McClellan Executive Vice President - Finance; Chief Financial Officer Senior Management 2019 -
Mercedes Diz Chief Marketing Officer Senior Management 2023 -
Volker Koscielny Chief Medical Officer Senior Management - -
Karl Ziegelbauer Executive Vice President - R&D; Chief Scientific Officer Senior Management 2021 -
Non Dignissim Eros Proin vel Convallis 2024 XY
Non Dignissim Eros Proin vel Convallis 2024 XY
Non Dignissim Eros Proin vel Convallis 2024 XY
Gain insight into Almirall SA key executives to enhance your sales strategy Gain insight into Almirall SA key executives to enhance your sales strategy Find out more
Still looking?

Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.

Explorer

Access more premium companies when you subscribe to Explorer

Get in touch about GlobalData Company reports

Contact the team or request a demo to find out how our data can drive your business forward